Threshold Pharmaceuticals Provides Clinical Trial Update From a Complete Phase 1/2 Clinical Trial of TH-302 in Combination With Chemotherapy
21 sept. 2009 08h45 HE
|
Threshold Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Sept. 21, 2009 (GLOBE NEWSWIRE) -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) today announced clinical trial results related to Threshold's clinical stage hypoxia-activated...